Phase II multicenter study of second-line FOLFIRI plus cetuximab (FLIER) in patients with KRAS wild-type metastatic colorectal cancer: Final analysis of survival and additional analysis of BRAF, PI3CA mutations.
Yasuhiro Miyake
No relevant relationships to disclose
Shigeyoshi Iwamoto
No relevant relationships to disclose
Shoichi Hazama
No relevant relationships to disclose
Fuminori Goda
No relevant relationships to disclose
Chu Matsuda
No relevant relationships to disclose
Kenji Amagai
No relevant relationships to disclose
HIroyuki Bandou
No relevant relationships to disclose
Mutsumi Fukunaga
No relevant relationships to disclose
Naoki Nagata
No relevant relationships to disclose
Junichi Sakamoto
No relevant relationships to disclose
Hideyuki Mishima
No relevant relationships to disclose